PLUS1
1.03
0.08 (8.42%)
0.08 (8.42%)
Upgrade to Real-Time
Market Closed
Low
0.60
High
1.92
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aptose Biosciences Inc | APS | Toronto | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.08 | 8.42% | 1.03 | 16:12:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.95 | 0.94 | 1.02 | 1.03 | 0.95 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 49 | 39,115 | - | 0.60 - 1.92 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 300 | $ 1.03 | CAD |
Period:
Draw Mode:
Aptose Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 87.68M | 91.04M | 91.04M | $ - | $ 0.00 | -0.92 | -1.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 184.75k | $ - | - | 0.00 | 1.40% |
Aptose Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.89 | 1.02 | 0.88 | 0.9299223 | 6,798 | 0.14 | 15.73% |
| 1 Month | 0.75 | 1.02 | 0.74 | 0.8865113 | 11,567 | 0.28 | 37.33% |
| 3 Months | 1.04 | 1.08 | 0.60 | 0.8584247 | 17,817 | -0.01 | -0.96% |
| 6 Months | 0.99 | 1.16 | 0.60 | 0.8681087 | 18,070 | 0.04 | 4.04% |
| 1 Year | 1.54 | 1.92 | 0.60 | 1.22 | 23,029 | -0.51 | -33.12% |
| 3 Years | 7.39 | 12.62 | 0.60 | 5.76 | 48,045 | -6.36 | -86.06% |
| 5 Years | 3.90 | 12.62 | 0.60 | 5.26 | 43,542 | -2.87 | -73.59% |
Aptose Biosciences Description
| Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. |